We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




ECCMID Congress Name Changes to ESCMID Global

By LabMedica International staff writers
Posted on 11 Apr 2024

Over the last few years, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) has evolved remarkably. More...

The society is now stronger and broader than ever before in the four decades since it was founded. Currently, ESCMID is focusing on stepping up the fight against antimicrobial resistance, advancing preparedness for emerging infections, and leading in the practice, education, and training of specialists. In recent years, ESCMID has welcomed over 4000 new members and expects to see a record-breaking 20,000 colleagues attend its congress in Barcelona. Hence, the organization feels the need to adapt to this new reality.

In 2023, ESCMID’s in-depth analysis of its brand and communication efforts revealed that the brand failed to adequately reflect ESCMID’s expanding global role. The analysis also revealed that most community members were unaware of various activities undertaken by ESCMID related to research, education, and guidelines. Additionally, most of its audience was unaware of the connection between the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and ESCMID. As a result, the society has now decided to strengthen its main brand, ESCMID, and bring all of its various sub-brands more closely together under one large ESCMID umbrella. This includes changing the name of its congress to “ESCMID Global”, creating a clear link to ESCMID, and conveying its outreach and perspective beyond Europe.

Simultaneously, ESCMID is modernizing its visual identity. As the society strives for pioneering research and state-of-the-art education, it also aims to communicate in an effective manner that will be suitable to the present time and also apt for the next decade. As a first step in these efforts, the organization has released its renewed website escmid.org. The upcoming ESCMID Global, formerly ECCMID, in Barcelona (27–30 April 2024) will be the society’s 34th congress and the first one with the new name and look.

Related Links:
ESCMID


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.